Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003;44:1797–1803.

• PubMed
Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003;44:1797–1803.14602862)| false
• Search Google Scholar
• Export Citation

De Wever W, Ceyssens S, Mortelmans L, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007;17:23–32.

• Crossref
• PubMed
De Wever W, Ceyssens S, Mortelmans L, Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007;17:23–32.10.1007/s00330-006-0284-4)| false
• Search Google Scholar
• Export Citation

Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500–2507.

• Crossref
• PubMed
Lardinois D, Weder W, Hany TF, Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500–2507.1281513510.1056/NEJMoa022136)| false
• Search Google Scholar
• Export Citation

Pelosi E, Messa C, Sironi S, et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 2004;31:932–939.

• Crossref
• PubMed
Pelosi E, Messa C, Sironi S, Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 2004;31:932–939.1499124510.1007/s00259-004-1483-3)| false
• Search Google Scholar
• Export Citation

Freudenberg LS, Antoch G, Schutt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004;31:325–329.

• Crossref
• PubMed
Freudenberg LS, Antoch G, Schutt P, FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004;31:325–329.1464798810.1007/s00259-003-1375-y)| false
• Search Google Scholar
• Export Citation

Larson SM, Schwartz LH. 18F-FDG PET as a candidate for “qualified biomarker”: functional assessment of treatment response in oncology. J Nucl Med 2006;47:901–903.

• PubMed
Larson SM, Schwartz LH. 18F-FDG PET as a candidate for “qualified biomarker”: functional assessment of treatment response in oncology. J Nucl Med 2006;47:901–903.16741296)| false
• Search Google Scholar
• Export Citation

Hartwell L, Mankoff D, Paulovich A, et al. Cancer biomarkers: a systems approach. Nat Biotechnol 2006;24:905–908.

• Crossref
• PubMed
Hartwell L, Mankoff D, Paulovich A, Cancer biomarkers: a systems approach. Nat Biotechnol 2006;24:905–908.10.1038/nbt0806-90516900126)| false
• Search Google Scholar
• Export Citation

Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005;43:153–167.

• Crossref
• PubMed
Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005;43:153–167.1569365410.1016/j.rcl.2004.09.005)| false
• Search Google Scholar
• Export Citation

Smith-Jones PM, Solit DB, Akhurst T, et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701–706.

• Crossref
• PubMed
Smith-Jones PM, Solit DB, Akhurst T, Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701–706.1513347110.1038/nbt968)| false
• Search Google Scholar
• Export Citation

Veach DR, Namavari M, Beresten T, et al. Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nucl Med Biol 2005;32:313–321.

• Crossref
• PubMed
Veach DR, Namavari M, Beresten T, Synthesis and in vitro examination of [¹²⁴I]-, [¹²⁵I]- and [¹³¹I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nucl Med Biol 2005;32:313–321.1587850010.1016/j.nucmedbio.2005.01.008)| false
• Search Google Scholar
• Export Citation

Hillner BE, Tunuguntla R, Fratkin M. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol 2004;22:4147–4156.

• Crossref
• PubMed
Hillner BE, Tunuguntla R, Fratkin M. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol 2004;22:4147–4156.10.1200/JCO.2004.12.115)| false
• Search Google Scholar
• Export Citation

van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388–1393.

• Crossref
• PubMed
van Tinteren H, Hoekstra OS, Smit EF, Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388–1393.10.1016/S0140-6736(02)08352-6)| false
• Search Google Scholar
• Export Citation

Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388–395.

• Crossref
• PubMed
Ruers TJ, Langenhoff BS, Neeleman N, Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388–395.1178656510.1200/JCO.2002.20.2.388)| false
• Search Google Scholar
• Export Citation

Wahl Rl, Siegel BA, Coleman RE, et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22: 277–285.

• Crossref
• PubMed
Wahl Rl, Siegel BA, Coleman RE, Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22: 277–285.10.1200/JCO.2004.04.148)| false
• Search Google Scholar
• Export Citation

Kumar R, Zhuang H, Schnall M, et al. PDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 2006;27:231–236.

• Crossref
• PubMed
Kumar R, Zhuang H, Schnall M, PDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 2006;27:231–236.10.1097/00006231-200603000-00005)| false
• Search Google Scholar
• Export Citation

Fehr MK, Hornung R, Varga Z, et al. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 2004;10:89–93.

• Crossref
• PubMed
Fehr MK, Hornung R, Varga Z, Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 2004;10:89–93.10.1111/j.1075-122X.2004.21455.x15009033)| false
• Search Google Scholar
• Export Citation

Barranger E, Grahek D, Antoine M, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastasis in patients with early-stage breast cancer. Ann Surg Oncol 2003;10:622–627.

• Crossref
• PubMed
Barranger E, Grahek D, Antoine M, Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastasis in patients with early-stage breast cancer. Ann Surg Oncol 2003;10:622–627.10.1245/ASO.2003.12.01912839846)| false
• Search Google Scholar
• Export Citation

Keleman PR, Lowe V, Phillips N. Positron emission tomography and sentinel node dissection in breast cancer. Clin Breast Cancer 2002;3:73–77.

• Crossref
• PubMed
Keleman PR, Lowe V, Phillips N. Positron emission tomography and sentinel node dissection in breast cancer. Clin Breast Cancer 2002;3:73–77.10.3816/CBC.2002.n.014)| false
• Search Google Scholar
• Export Citation

Veronesi U, De Cicco C, Galimberti V, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007;18:473–478.

• Crossref
• PubMed
Veronesi U, De Cicco C, Galimberti V, A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007;18:473–478.1716422910.1093/annonc/mdl425)| false
• Search Google Scholar
• Export Citation

Gil-Rendo A, Zornoza G, Garcia-Velloso MJ, et al. Fluorodeoxyglucose positron emission tomography with sentinel node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 2006;93:707–712.

• Crossref
• PubMed
Gil-Rendo A, Zornoza G, Garcia-Velloso MJ, Fluorodeoxyglucose positron emission tomography with sentinel node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 2006;93:707–712.1662290010.1002/bjs.5338)| false
• Search Google Scholar
• Export Citation

Zornoza G, Garcia-Velloso MJ, Sola J, et al. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 2004;30:15–19.

• Crossref
• PubMed
Zornoza G, Garcia-Velloso MJ, Sola J, ¹⁸F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 2004;30:15–19.10.1016/j.ejso.2003.10.01014736517)| false
• Search Google Scholar
• Export Citation

Hathaway PB, Mankoff DA, Maravilla KR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999;210:807–814.

• Crossref
• PubMed
Hathaway PB, Mankoff DA, Maravilla KR, Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999;210:807–814.10.1148/radiology.210.3.r99mr43807)| false
• Search Google Scholar
• Export Citation

Ahmad A, Barrington S, Maisey M, Rubens RD. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999;79: 478–482.

• Crossref
• PubMed
Ahmad A, Barrington S, Maisey M, Rubens RD. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999;79: 478–482.1002731610.1038/sj.bjc.6690074)| false
• Search Google Scholar
• Export Citation

Inoue T, Yutani K, Taguchi T, et al. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol 2004;130:273–278.

• Crossref
• PubMed
Inoue T, Yutani K, Taguchi T, Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol 2004;130:273–278.1498611210.1007/s00432-003-0536-5)| false
• Search Google Scholar
• Export Citation

Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43: 500–509.

• PubMed
Mankoff DA, Dunnwald LK, Gralow JR, Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43: 500–509.11937594)| false
• Search Google Scholar
• Export Citation

Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004;27:407–410.

• Crossref
• PubMed
Bellon JR, Livingston RB, Eubank WB, Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004;27:407–410.10.1097/01.coc.0000128869.19357.9b15289736)| false
• Search Google Scholar
• Export Citation

Norum J, Andreassen T. Screening for metastatic disease in newly diagnosed breast cancer patients. What is costeffective? Anticancer Res 2000;20:2193–2196.

• PubMed
Norum J, Andreassen T. Screening for metastatic disease in newly diagnosed breast cancer patients. What is costeffective? Anticancer Res 2000;20:2193–2196.)| false
• Search Google Scholar
• Export Citation

Puglisi F, Follador A, Minisini AM, et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:263–266.

• Crossref
• PubMed
Puglisi F, Follador A, Minisini AM, Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:263–266.10.1093/annonc/mdi06315668281)| false
• Search Google Scholar
• Export Citation

Barry MC, Thornton F, Murphy M, et al. The value of metastatic screening in early primary breast cancer. Ir J Med Sci 1999;168:248–250.

• Crossref
• PubMed
Barry MC, Thornton F, Murphy M, The value of metastatic screening in early primary breast cancer. Ir J Med Sci 1999;168:248–250.1062436310.1007/BF02944350)| false
• Search Google Scholar
• Export Citation

Moon DH, Maddahi J, Silverman DH, et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998; 39:431–435.

• PubMed
Moon DH, Maddahi J, Silverman DH, Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998; 39:431–435.9529287)| false
• Search Google Scholar
• Export Citation

Kamel EM, Wyss MT, Fehr MK, et al. [18-F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrent of breast cancer. J Cancer Res Clin Oncol 2003;129:147–153.

• Crossref
• PubMed
Kamel EM, Wyss MT, Fehr MK, [18-F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrent of breast cancer. J Cancer Res Clin Oncol 2003;129:147–153.10.1007/s00432-003-0424-z)| false
• Search Google Scholar
• Export Citation

Eubank WB, Mankoff DA, Takasugi J, et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001;19:3516–3523.

• Crossref
• PubMed
Eubank WB, Mankoff DA, Takasugi J, 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001;19:3516–3523.1148135810.1200/JCO.2001.19.15.3516)| false
• Search Google Scholar
• Export Citation

Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375–3379.

• Crossref
• PubMed
Cook GJ, Houston S, Rubens R, Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375–3379.10.1200/JCO.1998.16.10.33759779715)| false
• Search Google Scholar
• Export Citation

Abe K, Sasaki M, Kuwabara Y, et al. Comparison of 18 FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005;19:573–579.

• Crossref
• PubMed
Abe K, Sasaki M, Kuwabara Y, Comparison of 18 FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005;19:573–579.10.1007/BF02985050)| false
• Search Google Scholar
• Export Citation

Fujimoto R, Higashi T, Nakamoto Y, et al. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med 2006;20:399–408.

• Crossref
• PubMed
Fujimoto R, Higashi T, Nakamoto Y, Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med 2006;20:399–408.10.1007/BF0302737516922468)| false
• Search Google Scholar
• Export Citation

Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18)F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689–1695.

• Crossref
• PubMed
Schelling M, Avril N, Nahrig J, Positron emission tomography using [(18)F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689–1695.10.1200/JCO.2000.18.8.168910764429)| false
• Search Google Scholar
• Export Citation

Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F] fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676–1688.

• Crossref
• PubMed
Smith IC, Welch AE, Hutcheon AW, Positron emission tomography using [(18)F] fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676–1688.10.1200/JCO.2000.18.8.167610764428)| false
• Search Google Scholar
• Export Citation

Mankoff DA, Dunnwald LK. Changes in glucose metabolism and blood flow following chemotherapy for breast cancer. PET Clinics 2005;1:71–82.

• Crossref
• PubMed
Mankoff DA, Dunnwald LK. Changes in glucose metabolism and blood flow following chemotherapy for breast cancer. PET Clinics 2005;1:71–82.10.1016/j.cpet.2005.09.001)| false
• Search Google Scholar
• Export Citation

Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1815–1817.

• PubMed
Mankoff DA, Dunnwald LK, Gralow JR, Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1815–1817.)| false
• Search Google Scholar
• Export Citation

Kim SJ, Kim SK, Lee ES, et al. Predictive value of [18F]FDG PET for pathological response of breast cancer to neoadjuvant chemotherapy. Ann Oncol 2004;15:1352–1357.

• Crossref
• PubMed
Kim SJ, Kim SK, Lee ES, Predictive value of [18F]FDG PET for pathological response of breast cancer to neoadjuvant chemotherapy. Ann Oncol 2004;15:1352–1357.10.1093/annonc/mdh34515319241)| false
• Search Google Scholar
• Export Citation

Gennari A, Donatis S, Salvadori B, et al. Role of 2-[18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000;1:156–161.

• Crossref
• PubMed
Gennari A, Donatis S, Salvadori B, Role of 2-[18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000;1:156–161.10.3816/CBC.2000.n.01411899654)| false
• Search Google Scholar
• Export Citation

Dose Schwarz J, Bader M, Jenicke L, et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46: 1144–1150.

• PubMed
Dose Schwarz J, Bader M, Jenicke L, Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46: 1144–1150.)| false
• Search Google Scholar
• Export Citation

Stafford SE, Gralow JR, Schubert EK, et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002;9:913–921.

• Crossref
• PubMed
Stafford SE, Gralow JR, Schubert EK, Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 2002;9:913–921.1218644010.1016/S1076-6332(03)80461-0)| false
• Search Google Scholar
• Export Citation

Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004;230:417–422.

• Crossref
• PubMed
Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004;230:417–422.10.1148/radiol.230202168514699176)| false
• Search Google Scholar
• Export Citation

Yasuda S, Fujii H, Nakahara T, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med 2001;42:989–992.

• PubMed
Yasuda S, Fujii H, Nakahara T, 18F-FDG PET detection of colonic adenomas. J Nucl Med 2001;42:989–992.11438616)| false
• Search Google Scholar
• Export Citation

Llamas-Elvira JM, Rodriguez-Fernandez A, Gutierrez-Sainz J, et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 2006;Dec 29 [Epub ahead of print].

• PubMed
Llamas-Elvira JM, Rodriguez-Fernandez A, Gutierrez-Sainz J, Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 2006;Dec 29 [Epub ahead of print].17195075)| false
• Search Google Scholar
• Export Citation

Kantorova I, Lipska L, Belohlavek O, et al. Routine (18)FFDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003;44:1784–1788.

• PubMed
Kantorova I, Lipska L, Belohlavek O, Routine (18)FFDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003;44:1784–1788.)| false
• Search Google Scholar
• Export Citation

Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206:755–760.

• Crossref
• PubMed
Abdel-Nabi H, Doerr RJ, Lamonica DM, Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206:755–760.10.1148/radiology.206.3.94944979494497)| false
• Search Google Scholar
• Export Citation

Mukai M, Sadahiro S, Yasuda S, et al. Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep 2000;7:85–87.

• PubMed
Mukai M, Sadahiro S, Yasuda S, Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep 2000;7:85–87.10601597)| false
• Search Google Scholar
• Export Citation

Desch CE, Benson AB III, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23:8512–8519. Erratum in J Clin Oncol 2006;24:1224.

• Crossref
• PubMed
Desch CE, Benson AB III, Somerfield MR, Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23:8512–8519. Erratum in J Clin Oncol 2006;24:1224.10.1200/JCO.2005.04.0063)| false
• Search Google Scholar
• Export Citation

Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177–1189.

• PubMed
Huebner RH, Park KC, Shepherd JE, A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177–1189.10914907)| false
• Search Google Scholar
• Export Citation

Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517–522.

• Crossref
• PubMed
Schiepers C, Penninckx F, De Vadder N, Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517–522.10.1016/S0748-7983(95)97046-0)| false
• Search Google Scholar
• Export Citation

Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748–756.

• Crossref
• PubMed
Kinkel K, Lu Y, Both M, Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748–756.1220270910.1148/radiol.2243011362)| false
• Search Google Scholar
• Export Citation

Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis— meta-analysis. Radiology 2005;237:123–131.

• Crossref
• PubMed
Bipat S, van Leeuwen MS, Comans EF, Colorectal liver metastases: CT, MR imaging, and PET for diagnosis— meta-analysis. Radiology 2005;237:123–131.1610008710.1148/radiol.2371042060)| false
• Search Google Scholar
• Export Citation

Valk PE, Abella-Columna E, Haseman MK, et al. Wholebody PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503–511.

• Crossref
• PubMed
Valk PE, Abella-Columna E, Haseman MK, Wholebody PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503–511.10.1001/archsurg.134.5.503)| false
• Search Google Scholar
• Export Citation

Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001;37:862–869.

• Crossref
• PubMed
Flamen P, Hoekstra OS, Homans F, Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001;37:862–869.10.1016/S0959-8049(01)00049-111313174)| false
• Search Google Scholar
• Export Citation

Maldonado A, Sancho F, Cerdan J, et al. 16. FDG-PET in the detection of recurrence in colorectal cancer based on rising CEA level. Experience in 72 Patients. Clin Positron Imaging 2000;3:170.

• Crossref
• PubMed
Maldonado A, Sancho F, Cerdan J, 16. FDG-PET in the detection of recurrence in colorectal cancer based on rising CEA level. Experience in 72 Patients. Clin Positron Imaging 2000;3:170.10.1016/S1095-0397(00)00082-0)| false
• Search Google Scholar
• Export Citation

Flanagan FL, Dehdashti F, Ogunbiyi OA, et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319–323.

• Crossref
• PubMed
Flanagan FL, Dehdashti F, Ogunbiyi OA, Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319–323.10.1097/00000658-199803000-000019527052)| false
• Search Google Scholar
• Export Citation

Wiering B, Krabbe PF, Jager GJ, et al. The impact of fluor18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005;104:2658–2670.

• Crossref
• PubMed
Wiering B, Krabbe PF, Jager GJ, The impact of fluor18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005;104:2658–2670.1631524110.1002/cncr.21569)| false
• Search Google Scholar
• Export Citation

Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196–1201.

• PubMed
Delbeke D, Vitola JV, Sandler MP, Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196–1201.9255148)| false
• Search Google Scholar
• Export Citation

Strasberg SM, Dehdashti F, Siegel BA, et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001;233:293–299.

• Crossref
• PubMed
Strasberg SM, Dehdashti F, Siegel BA, Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001;233:293–299.10.1097/00000658-200103000-0000111224615)| false
• Search Google Scholar
• Export Citation

Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438–447.

• Crossref
• PubMed
Fernandez FG, Drebin JA, Linehan DC, Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438–447.1531971510.1097/01.sla.0000138076.72547.b1)| false
• Search Google Scholar
• Export Citation

Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700–708.

• Crossref
• PubMed
Findlay M, Young H, Cunningham D, Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700–708.862201410.1200/JCO.1996.14.3.700)| false
• Search Google Scholar
• Export Citation

Guillem JG, Puig-La Calle J Jr, Akhurst T, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000;43:18–24.

• Crossref
• PubMed
Guillem JG, Puig-La Calle J Jr, Akhurst T, Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000;43:18–24.10.1007/BF0223723810813118)| false
• Search Google Scholar
• Export Citation

Donckier V, Van Laethem JL, Goldman S, et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003;84:215–223.

• Crossref
• PubMed
Donckier V, Van Laethem JL, Goldman S, [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003;84:215–223.10.1002/jso.1031414756432)| false
• Search Google Scholar
• Export Citation

Wong CY, Qing F, Savin M, et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 2005;16:1101–1106.

• Crossref
• PubMed
Wong CY, Qing F, Savin M, Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 2005;16:1101–1106.10.1097/01.RVI.0000168104.32849.0716105922)| false
• Search Google Scholar
• Export Citation

Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 2004;45:1892–1897.

• PubMed
Wong CY, Salem R, Qing F, Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 2004;45:1892–1897.15534060)| false
• Search Google Scholar
• Export Citation

Barker DW, Zagoria RJ, Morton Ka, et al. Evaluation of liver metastases after radiofrequency ablation: utility of 18FFDG PET and PET/CT. AJR Am J Roentgenol 2005;184:1096–1102.

• Crossref
• PubMed
Barker DW, Zagoria RJ, Morton Ka, Evaluation of liver metastases after radiofrequency ablation: utility of 18FFDG PET and PET/CT. AJR Am J Roentgenol 2005;184:1096–1102.10.2214/ajr.184.4.01841096)| false
• Search Google Scholar
• Export Citation

Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2005;23:4643–4651.

• Crossref
• PubMed
Schoder H, Noy A, Gonen M, Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2005;23:4643–4651.10.1200/JCO.2005.12.07215837966)| false
• Search Google Scholar
• Export Citation

Bangerter M, Moog F, Buchmann I, et al. Whole-body 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 1998;9:1117–1122.

• Crossref
• PubMed
Bangerter M, Moog F, Buchmann I, Whole-body 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 1998;9:1117–1122.10.1023/A:10084869281909834825)| false
• Search Google Scholar
• Export Citation

Young CS, Young BL, Smith SM. Staging Hodgkin’s disease with 18-FDG PET. Comparison with CT and surgery. Clin Positron Imaging 1998;1:161–164.

• Crossref
• PubMed
Young CS, Young BL, Smith SM. Staging Hodgkin’s disease with 18-FDG PET. Comparison with CT and surgery. Clin Positron Imaging 1998;1:161–164.1451659010.1016/S1095-0397(98)00011-9)| false
• Search Google Scholar
• Export Citation

Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958–963.

• PubMed
Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958–963.15937306)| false
• Search Google Scholar
• Export Citation

Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006;47:1267–1273.

• PubMed
Bruzzi JF, Macapinlac H, Tsimberidou AM, Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006;47:1267–1273.16883004)| false
• Search Google Scholar
• Export Citation

Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored International Working Group. J Clin Oncol 1999;17:1244. Erratum in J Clin Oncol 2000;18:2351.

• Crossref
• PubMed
Cheson BD, Horning SJ, Coiffier B, Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored International Working Group. J Clin Oncol 1999;17:1244. Erratum in J Clin Oncol 2000;18:2351.10.1200/JCO.1999.17.4.1244)| false
• Search Google Scholar
• Export Citation

Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003;30(suppl 1):S89–S96.

• Crossref
• PubMed
Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003;30(suppl 1):S89–S96.1274882910.1007/s00259-003-1167-4)| false
• Search Google Scholar
• Export Citation

Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414–419.

• Crossref
• PubMed
Spaepen K, Stroobants S, Dupont P, Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414–419.1120883310.1200/JCO.2001.19.2.414)| false
• Search Google Scholar
• Export Citation

Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930–2934.

• Crossref
• PubMed
Weihrauch MR, Re D, Scheidhauer K, Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98:2930–2934.1169827310.1182/blood.V98.10.2930)| false
• Search Google Scholar
• Export Citation

Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol 2001;115:793–800.

• Crossref
• PubMed
Naumann R, Vaic A, Beuthien-Baumann B, Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol 2001;115:793–800.10.1046/j.1365-2141.2001.03147.x11843811)| false
• Search Google Scholar
• Export Citation

Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop criteria and fluorine18-fluorodeoxxyglucose positron emission tomography. J Clin Oncol 2005;23:4652–4661.

• Crossref
• PubMed
Juweid ME, Wiseman GA, Vose JM, Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop criteria and fluorine18-fluorodeoxxyglucose positron emission tomography. J Clin Oncol 2005;23:4652–4661.1583796510.1200/JCO.2005.01.891)| false
• Search Google Scholar
• Export Citation

Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 2007;25:571–578.

• Crossref
• PubMed
Juweid ME, Stroobants S, Hoekstra OS, Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 2007;25:571–578.1724239710.1200/JCO.2006.08.2305)| false
• Search Google Scholar
• Export Citation

Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25: 579–586.

• Crossref
• PubMed
Cheson BD, Pfistner B, Juweid ME, Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25: 579–586.10.1200/JCO.2006.09.240317242396)| false
• Search Google Scholar
• Export Citation

Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52–59.

• Crossref
• PubMed
Hutchings M, Loft A, Hansen M, FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52–59.1615094410.1182/blood-2005-06-2252)| false
• Search Google Scholar
• Export Citation

Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514–1523.

• Crossref
• PubMed
Mikhaeel NG, Hutchings M, Fields PA, FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514–1523.10.1093/annonc/mdi27215980161)| false
• Search Google Scholar
• Export Citation

Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxyD-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376–1381.

• Crossref
• PubMed
Haioun C, Itti E, Rahmouni A, [18F]fluoro-2-deoxyD-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376–1381.1586066610.1182/blood-2005-01-0272)| false
• Search Google Scholar
• Export Citation

Patterson GA, Ginsberg RJ, Poon PY, et al. A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J Thorac Cardiovasc Surg 1987;94:679–684.

• Crossref
• PubMed
Patterson GA, Ginsberg RJ, Poon PY, A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J Thorac Cardiovasc Surg 1987;94:679–684.366969610.1016/S0022-5223(19)36180-X)| false
• Search Google Scholar
• Export Citation

Alongi F, Ragusa P, Montemaggi P, Bona CM. Combining independent studies of diagnostic fluorodeoxyglucose positron-emission tomography and computed tomography in mediastinal lymph node staging for non small cell lung cancer. Tumori 2006;92:327–333.

• Crossref
• PubMed
Alongi F, Ragusa P, Montemaggi P, Bona CM. Combining independent studies of diagnostic fluorodeoxyglucose positron-emission tomography and computed tomography in mediastinal lymph node staging for non small cell lung cancer. Tumori 2006;92:327–333.1703652510.1177/030089160609200412)| false
• Search Google Scholar
• Export Citation

Herder GJ, Kramer H, Hoekstra OS, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006;24: 1800–1806.

• Crossref
• PubMed
Herder GJ, Kramer H, Hoekstra OS, Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006;24: 1800–1806.1656777210.1200/JCO.2005.02.4695)| false
• Search Google Scholar
• Export Citation

Bruzzi JF, Munden RF. PET/CT imaging of lung cancer. J Thoracic Imaging 2006;21:123–126.

• Crossref
• PubMed
Bruzzi JF, Munden RF. PET/CT imaging of lung cancer. J Thoracic Imaging 2006;21:123–126.10.1097/00005382-200605000-00004)| false
• Search Google Scholar
• Export Citation

Allen-Auerbach M, Yeom K, Park J, et al. Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med 2006;47: 298–301.

• PubMed
Allen-Auerbach M, Yeom K, Park J, Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med 2006;47: 298–301.16455636)| false
• Search Google Scholar
• Export Citation

Gilman MD, Fischman AJ, Krishnasetty V, et al. Optimal CT breathing protocol for combined thoracic PET/CT. AJR Am J Roentgenol 2006;187:1357–1360.

• Crossref
• PubMed
Gilman MD, Fischman AJ, Krishnasetty V, Optimal CT breathing protocol for combined thoracic PET/CT. AJR Am J Roentgenol 2006;187:1357–1360.10.2214/AJR.05.142717056929)| false
• Search Google Scholar
• Export Citation

Nehmeh SA, Erdi YE, Meirelles GS, et al. Deep-inspiration on breath-hold of PET/CT of the thorax. J Nucl Med 2007;48:22–26.

• PubMed
Nehmeh SA, Erdi YE, Meirelles GS, Deep-inspiration on breath-hold of PET/CT of the thorax. J Nucl Med 2007;48:22–26.17204695)| false
• Search Google Scholar
• Export Citation

Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006;131:1229–1235.

• Crossref
• PubMed
Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006;131:1229–1235.10.1016/j.jtcvs.2005.08.07016733150)| false
• Search Google Scholar
• Export Citation

Granome P, van Schil P, Cesario A. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a closer look at redo mediastinoscopy. Letter to the Editor. J Thorac Cardiovasc Surg 2007;133: 275–276.

• Crossref
• PubMed
Granome P, van Schil P, Cesario A. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a closer look at redo mediastinoscopy. Letter to the Editor. J Thorac Cardiovasc Surg 2007;133: 275–276.10.1016/j.jtcvs.2006.06.049)| false
• Search Google Scholar
• Export Citation

Pottgen C, Levegrun S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006;12:97–106.

• Crossref
• PubMed
Pottgen C, Levegrun S, Theegarten D, Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006;12:97–106.1639703010.1158/1078-0432.CCR-05-0510)| false
• Search Google Scholar
• Export Citation

Cerfolio RJ, Bryant AS, Winokur TS, et al. Repeat FDGPET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903–1909.

• Crossref
• PubMed
Cerfolio RJ, Bryant AS, Winokur TS, Repeat FDGPET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903–1909.10.1016/j.athoracsur.2004.06.102)| false
• Search Google Scholar
• Export Citation

Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantita-tive assessment of glucose use. J Clin Oncol 2003;21:2651–2657.